Spruce Biosciences (SPRB) Accounts Payables (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Accounts Payables of $298000.0 for Q1 2026, down 68.4% quarter-over-quarter from $943000.0 in Q4 2025.
Spruce Biosciences (SPRB) Accounts Payables (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Accounts Payables for 8 consecutive years, with $298000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables changed N/A year-over-year to $298000.0; the TTM figure through Mar 2026 stood at $298000.0 (changed N/A YoY), while the FY2025 annual figure was $943000.0, down 27.18% from the prior year.
- Accounts Payables eased to $298000.0 in Q1 2026 per SPRB's latest filing, from $943000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $3.4 million in Q1 2023 and bottomed at $298000.0 in Q1 2026.
- Historically, Accounts Payables has averaged $1.6 million across 5 years, with a median of $1.4 million in 2022.
- Annual changes were most pronounced in 2023 — Accounts Payables jumped 210.91% — and 2024, when it sank 61.13%.
- Spruce Biosciences' Accounts Payables stood at $1.4 million in 2022, then surged by 133.66% to $3.3 million in 2023, then tumbled by 61.13% to $1.3 million in 2024, then decreased by 27.18% to $943000.0 in 2025, then sank by 68.4% to $298000.0 in 2026.
- Business Quant data shows SPRB's Accounts Payables at $298000.0 in Q1 2026, $943000.0 in Q4 2025, and $1.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 35.57 Mn |
| 10 | Spruce Biosciences | 125.22 Mn | 125.22 Mn | - | 1.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.21 Mn |
| Mar 31, 2026 | 298,000.00 |
| Dec 31, 2025 | 943,000.00 |
| Sep 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 807,000.00 |
| Dec 31, 2024 | 1.30 Mn |
| Sep 30, 2024 | 1.80 Mn |
| Jun 30, 2024 | 682,000.00 |
| Mar 31, 2024 | 1.89 Mn |
| Dec 31, 2023 | 3.33 Mn |
| Sep 30, 2023 | 3.15 Mn |
| Jun 30, 2023 | 945,000.00 |
| Mar 31, 2023 | 3.45 Mn |
| Dec 31, 2022 | 1.43 Mn |
| Sep 30, 2022 | 2.18 Mn |
| Jun 30, 2022 | 1.45 Mn |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | 2.82 Mn |
| Sep 30, 2021 | 2.13 Mn |
| Jun 30, 2021 | 1.11 Mn |